Ironwood Pharmaceuticals
IRWD
249 hedge funds and large institutions have $2.03B invested in Ironwood Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 93 increasing their positions, 88 reducing their positions, and 22 closing their positions.
5,611% more call options, than puts
Call options by funds: $1.6M | Put options by funds: $28K
32% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 22
16% more capital invested
Capital invested by funds: $1.76B → $2.03B (+$275M)
2% more funds holding
Funds holding: 245 → 249 (+4)
6% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 88
3.74% less ownership
Funds ownership: 110.76% → 107.02% (-3.7%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$24.8M |
| 2 |
Two Sigma Investments
New York
|
+$16.1M |
| 3 |
JP Morgan Chase
New York
|
+$16M |
| 4 |
Two Sigma Advisers
New York
|
+$13.6M |
| 5 |
BlackRock
New York
|
+$9.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$52.6M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$15.7M |
| 3 |
Renaissance Technologies
New York
|
-$11.3M |
| 4 |
BM
Bridger Management
New York
|
-$9.49M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$7.71M |
IRWD Hedge Fund Activity: Q4 2022 in Review
249 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q4 2022, worth a combined $2.03B — up 16% from $1.76B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new IRWD positions and 22 closed out — a net gain of 7 holders — while 93 added to existing stakes and 88 trimmed.
The largest buyer was Millennium Management, adding an estimated $24.8M. The largest seller was Brown Capital Management, cutting an estimated $52.6M.
- 249 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q4 2022, up from 245 in Q3 2022.
- Funds reported $2.03B of Ironwood Pharmaceuticals stock for Q4 2022, up 16% quarter-over-quarter.
- 29 funds opened new Ironwood Pharmaceuticals positions in Q4 2022 and 22 closed out, a net change of +7 holders.
- The largest Ironwood Pharmaceuticals buyer in Q4 2022 was Millennium Management, an estimated $24.8M added.
- The largest Ironwood Pharmaceuticals seller in Q4 2022 was Brown Capital Management, an estimated $52.6M sold.
Based on aggregated 13F filings for Q4 2022.